Search research articles
Contact Us
Filters
Showing results (1-10 of 6) with videos related to
Page
of 1
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 1, 2007
Liposomal doxorubicin and the accelerated approval process
George Tidmarsh
Clinical Advances in Hematology & Oncology : H&O
|
March 10, 2012
The generic drug shortage
George Tidmarsh
Disease Models & Mechanisms
|
July 6, 2013
Linking academia and industry to bring drugs to the clinic: an interview with George Tidmarsh
George Tidmarsh
Pediatrics
|
December 15, 2023
Angiotensin-II Use for Refractory Hypotension in an Infant With Bilateral Renal Agenesis
Sheila Razdan, Alexis S Davis, George Tidmarsh, et al.
Biochimica Et Biophysica Acta
|
December 26, 2015
Combination of galectin inhibitor GCS-100 and BH3 mimetics eliminates both p53 wild type and p53 null AML cells
Peter P Ruvolo, Vivian R Ruvolo, Christopher B Benton, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 20, 2005
Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma
John P Leonard, Morton Coleman, Lale Kostakoglu, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 6) with videos related to
Sort By:
Page
of 1
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 1, 2007
Liposomal doxorubicin and the accelerated approval process
George Tidmarsh
Clinical Advances in Hematology & Oncology : H&O
|
March 10, 2012
The generic drug shortage
George Tidmarsh
Disease Models & Mechanisms
|
July 6, 2013
Linking academia and industry to bring drugs to the clinic: an interview with George Tidmarsh
George Tidmarsh
Pediatrics
|
December 15, 2023
Angiotensin-II Use for Refractory Hypotension in an Infant With Bilateral Renal Agenesis
Sheila Razdan, Alexis S Davis, George Tidmarsh, et al.
Biochimica Et Biophysica Acta
|
December 26, 2015
Combination of galectin inhibitor GCS-100 and BH3 mimetics eliminates both p53 wild type and p53 null AML cells
Peter P Ruvolo, Vivian R Ruvolo, Christopher B Benton, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 20, 2005
Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma
John P Leonard, Morton Coleman, Lale Kostakoglu, et al.
Page
of 1